230 related articles for article (PubMed ID: 24248816)
1. Prognostic value of epidermal growth factor receptor mutations in resected lung adenocarcinomas.
Liu WS; Zhao LJ; Pang QS; Yuan ZY; Li B; Wang P
Med Oncol; 2014 Jan; 31(1):771. PubMed ID: 24248816
[TBL] [Abstract][Full Text] [Related]
2. [Predictive role of EGFR mutation status on postoperative prognosis in patients with resected lung adenocarcinomas].
Dong Y; Li Y; Peng H; Jin B; Huang A; Bai H; Xiong H; Han B
Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):177-83. PubMed ID: 23601297
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of EGFR mutations in surgically resected pathological stage I lung adenocarcinoma.
Nishii T; Yokose T; Miyagi Y; Daigo Y; Isaka T; Furumoto H; Ito H; Murakami S; Kondo T; Saito H; Oshita F; Yamada K; Matsukuma S; Nakayama H; Masuda M
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e204-e211. PubMed ID: 27349355
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma.
Renaud S; Seitlinger J; Guerrera F; Reeb J; Beau-Faller M; Voegeli AC; Siat J; Clément-Duchêne C; Tiotiu A; Santelmo N; Costardi L; Ruffini E; Falcoz PE; Vignaud JM; Massard G
Ann Surg Oncol; 2018 Apr; 25(4):1069-1078. PubMed ID: 29362963
[TBL] [Abstract][Full Text] [Related]
5. Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.
Ohba T; Toyokawa G; Kometani T; Nosaki K; Hirai F; Yamaguchi M; Hamatake M; Seto T; Ichinose Y; Sugio K
Surg Today; 2014 Mar; 44(3):478-86. PubMed ID: 23609009
[TBL] [Abstract][Full Text] [Related]
6. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
Xu L; Guo R
Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
[TBL] [Abstract][Full Text] [Related]
7. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma.
Lee YJ; Park IK; Park MS; Choi HJ; Cho BC; Chung KY; Kim SK; Chang J; Moon JW; Kim H; Choi SH; Kim JH
J Cancer Res Clin Oncol; 2009 Dec; 135(12):1647-54. PubMed ID: 19517135
[TBL] [Abstract][Full Text] [Related]
9. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of EGFR Driver Mutations on Postoperative Disease Recurrence in Lung Adenocarcinoma.
Okamoto T; Kitahara H; Shimamatsu S; Katsura M; Takada K; Fujishita T; Suzuki Y; Morodomi Y; Tagawa T; Maehara Y
Anticancer Res; 2016 Jun; 36(6):3057-63. PubMed ID: 27272827
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impacts of EGFR mutation status and subtype in patients with surgically resected lung adenocarcinoma.
Takamochi K; Oh S; Matsunaga T; Suzuki K
J Thorac Cardiovasc Surg; 2017 Nov; 154(5):1768-1774.e1. PubMed ID: 28826599
[TBL] [Abstract][Full Text] [Related]
12. Epidermal Growth Factor Receptor Mutations and Prognosis in Pathologic N1-N2 Pulmonary Adenocarcinoma.
Isaka T; Nakayama H; Yokose T; Ito H; Miyagi Y; Matsuzaki T; Nagata M; Furumoto H; Nishii T; Katayama K; Yamada K; Masuda M
Ann Thorac Surg; 2016 Dec; 102(6):1821-1828. PubMed ID: 27553497
[TBL] [Abstract][Full Text] [Related]
13. Differential Prognostic Value of Vascular Invasion in Resected Lung Adenocarcinomas According to Epidermal Growth Factor Receptor Mutational Status.
Lee KH; Chung JH; Cho S; Lee JS; Kim H
Clin Lung Cancer; 2023 Nov; 24(7):e291-e299.e1. PubMed ID: 37479587
[TBL] [Abstract][Full Text] [Related]
14. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
15. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Janjigian YY; Park BJ; Zakowski MF; Ladanyi M; Pao W; D'Angelo SP; Kris MG; Shen R; Zheng J; Azzoli CG
J Thorac Oncol; 2011 Mar; 6(3):569-75. PubMed ID: 21150674
[TBL] [Abstract][Full Text] [Related]
16. Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
D'Angelo SP; Janjigian YY; Ahye N; Riely GJ; Chaft JE; Sima CS; Shen R; Zheng J; Dycoco J; Kris MG; Zakowski MF; Ladanyi M; Rusch V; Azzoli CG
J Thorac Oncol; 2012 Dec; 7(12):1815-1822. PubMed ID: 23154553
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
[TBL] [Abstract][Full Text] [Related]
18. Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer.
Lim KH; Huang MJ; Liu HC; Kuo HT; Tzen CY; Hsieh RK
Med Oncol; 2007; 24(4):388-93. PubMed ID: 17917087
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of cyclooxygenase-2 levels can predict EGFR mutations and the efficacy of EGFR-TKI in patients with lung adenocarcinoma.
Li H; Wang Y; Su F; Li J; Gong P
Int J Clin Exp Pathol; 2015; 8(5):5577-83. PubMed ID: 26191267
[TBL] [Abstract][Full Text] [Related]
20. Clinical value of the new International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification of lung adenocarcinoma.
Guo Z; Yi F; Yin W; Zhang Y; Li Q; Gu Y; Xiao Y; Cao B; Ma L; Liang L
Thorac Cancer; 2017 May; 8(3):159-169. PubMed ID: 28220630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
